伊博加及其主要生物碱,伊博加因和去利博加因,引起了研究人员和从业者的兴趣,主要是由于它们在治疗物质使用障碍(SUDs)方面的推定功效。对于许多SUD来说,仍然没有有效的药物疗法。iboga生物碱的独特精神和躯体作用使它们与LSD等经典致幻剂区分开来,mescaline,和psilocybin。
研究小组进行了这项系统评价,重点是涉及伊博加因和去利博加因的临床数据和治疗干预。
该团队根据PRISMA指南使用PubMed和Embase搜索了截至2020年12月7日的所有出版物。
总共,我们确认了743条记录.在这次审查中,我们考虑24项研究,其中包括705名接受伊博加因或去利博加因的患者。这篇综述包括两个随机的,双盲,对照临床试验,一项双盲对照临床试验,17项开放标签研究或病例系列(包括观察性或回顾性研究),三个病例报告,和一项回顾性调查。已发表的数据表明,伊博加因是SUD背景下的有效治疗干预措施,减少戒断症状和渴望。数据还指出了对抑郁和创伤相关心理症状的有益影响。然而,研究报告了严重的医疗并发症和死亡,这似乎与伊博加因的神经和心脏毒性作用有关。在本综述中纳入的24项研究中描述了其中2例死亡。
SUDs和持续合并症的治疗需要创新的治疗方法。快速起效的疗法,例如伊波加因的应用,可能会为特定的个体提供新的治疗机会。医疗环境中严格的研究设计对于保证安全应用是必要的,监测,and,可能,医疗干预。
Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and psilocybin.
The study team performed this systematic
review focusing on clinical data and therapeutic interventions involving
ibogaine and noribogaine.
The team conducted a search for all publications up to December 7, 2020, using PubMed and Embase following PRISMA guidelines.
In total, we identified 743 records. In this
review, we consider 24 studies, which included 705 individuals receiving
ibogaine or noribogaine. This
review includes two randomized, double-blind, controlled clinical trials, one double-blind controlled clinical trial, 17 open-label studies or case series (including observational or retrospective studies), three case reports, and one retrospective survey. The published data suggest that ibogaine is an effective therapeutic intervention within the context of SUDs, reducing withdrawal symptoms and craving. Data also point toward a beneficial impact on depressive and trauma-related psychological symptoms. However, studies have reported severe medical complications and deaths, which seem to be associated with neuro- and cardiotoxic effects of ibogaine. Two of these fatalities were described in the 24 studies included in this
review.
Treatment of SUDs and persisting comorbidities requires innovative treatment approaches. Rapid-onset therapies such as the application of ibogaine may offer novel treatment opportunities for specific individuals. Rigorous study designs within medical settings are necessary to warrant safe application, monitoring, and, possibly, medical intervention.